S1806
SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive
Trial overview
Disease | Bladder cancer treatment and diagnosis |
Topic | S1806 |
Description | Primary Objective:To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).Patient Population:Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0). |
Physicians | Dr. Alvaro A. MartinezMD, FACR, FABS, FASTRO Radiation Oncologist Works at 5 centers.Dr. Frank A. ViciniMD, FACR, FASTRO Radiation oncologist Works at 3 centers.Dr. Larry L. KestinMD, FACR Radiation Oncologist Works at 3 centers.Dr. Thomas BoikeMD Radiation Oncologist Works at 3 centers.Dr. Michael I. GhilezanMD, PhD Radiation Oncologist Works at 4 centers.Dr. John Vito AntonucciMD Radiation Oncologist Works at 4 centers. |